Use of il17rb in the auxiliary screening or diagnosis of chronic kidney disease

Abstract

The application belongs to the technical field of kidney disease diagnosis, and particularly relates to application of IL17RB in auxiliary screening or diagnosis of chronic kidney disease. The application finds that the expression level of IL17RB is significantly up-regulated in glomerular podocytes of patients with four most common chronic kidney diseases, shows good diagnostic performance in distinguishing kidney disease patients from kidney healthy persons, and has potential value as a "warning" molecule in screening and auxiliary diagnosis of chronic kidney disease; the expression level of IL17RB is negatively correlated with the expression of a podocyte marker Synaptopodin, and has application value in monitoring podocyte function; the expression change of IL17RB can reflect that the glomerulus is in an abnormal state, is related to the severity of the disease, and has potential as a glomerular injury marker.

Description

Technical Field

[0001] This invention belongs to the field of kidney disease diagnostic technology, specifically relating to the application of IL17RB in the auxiliary screening or diagnosis of chronic kidney disease. Background Technology

[0002] Chronic kidney disease (CKD) refers to diseases caused by various factors that result in structural or functional abnormalities of the kidneys lasting for more than 3 months. Because the kidneys have a strong compensatory capacity, patients often have no obvious symptoms in the early stages of the disease. However, as the disease progresses, kidney function progressively declines, eventually leading to end-stage renal disease (ESRD). Minimal change disease (MCD), membranous nephropathy (MN), IgA nephropathy (IgAN), and diabetic nephropathy (DKD) are the four most common chronic kidney diseases. These diseases often affect the glomeruli and damage the filtration barrier, manifesting as varying degrees of proteinuria, hematuria, edema, and hypertension. MCD is the main cause of idiopathic nephrotic syndrome, accounting for approximately 10%-15% of adult nephrotic syndrome cases. Clinically, it presents typically as nephrotic syndrome, and some patients may experience complications such as infection, thrombosis, and acute kidney injury. MN is an autoimmune glomerular disease and also one of the common causes of adult nephrotic syndrome, accounting for approximately 23.4% of glomerular diseases, and its incidence is on the rise. MN has an insidious onset, typically presenting as nephrotic syndrome, and is often complicated by thrombosis and hypertension. Approximately one-third of MN patients may progress to ESRD within 10 years, with progressive renal function impairment and thrombotic complications being its main risks. IgAN is the most common primary glomerulonephritis worldwide, characterized by IgA deposition in the glomerular mesangial area, leading to mesangial cell proliferation and increased matrix, clinically manifesting as proteinuria and hematuria. IgAN progresses insidiously, with 30%-40% of patients progressing to ESRD within 10-20 years of onset. Complement activation-mediated glomerular inflammation is a key factor driving IgAN progression. Diabetes is the most common cause of chronic kidney disease. Approximately half of patients with type 2 diabetes and one-third of patients with type 1 diabetes will progress to chronic kidney disease, and it is also the leading cause of ESRD. Its pathological changes include glomerular basement membrane thickening, mesangial expansion, and podocyte damage, clinically manifesting as proteinuria and a progressive decline in glomerular filtration rate.

[0003] Although the four glomerular diseases mentioned above differ in etiology and pathogenesis, they all share glomerular structural damage and functional decline as their main pathological features. The glomerulus is the structural basis of filtration function, and the filtration barrier consists of three core layers from the inside out: capillary endothelial cells, the glomerular basement membrane, and the outermost podocytes. Podocytes are not only the outermost defensive barrier of the filtration barrier but also a cell type with extremely weak self-repair capabilities after injury, playing a crucial role in maintaining the integrity of the filtration barrier. In various glomerular diseases, podocyte damage is a core link in proteinuria production and disease progression, and detecting changes in the expression of its specific biomarkers can provide important clues for elucidating the molecular mechanisms of these diseases. The main podocyte-specific biomarkers include WT1, Synaptopodin, α-actinin-4, Nephrin, and Podocin. Among them, WT1 is a nuclear marker of podocytes, crucial for maintaining podocyte development and maturation; Synaptopodin and α-actinin-4 are podocyte skeletal protein markers, primarily responsible for maintaining normal cell structure and dynamics; Nephrin and Podocin are slit diaphragm markers, serving as core structures to prevent protein leakage and jointly ensuring the integrity of the filtration barrier. However, the downregulation or altered localization of these podocyte structural protein markers are usually only detected after substantial structural damage to podocytes (such as foot process fusion). This significant lag limits their application in early disease diagnosis. Therefore, finding markers that transcend specific site limitations and comprehensively reflect overall pathological damage to podocytes is a crucial breakthrough direction for achieving early identification and targeted intervention in kidney diseases. Summary of the Invention

[0004] To address the above-mentioned technical problems, this invention provides the application of IL17RB (interleukin-17 receptor B, Uniprot: Q9NRM6; NCBI: NM_018725, NP_061195.2) in the auxiliary screening or diagnosis of chronic kidney disease. Through research, this invention has found that the expression level of IL17RB is significantly upregulated in the renal parenchymal cells of patients with the four most common chronic kidney diseases, demonstrating good diagnostic performance in distinguishing kidney disease patients from healthy individuals. It has potential value as a "warning" molecule in the screening and auxiliary diagnosis of chronic kidney disease. The expression level of IL17RB is negatively correlated with the expression of Synaptopodin and is located in podocytes, indicating its application value in monitoring podocyte function. Changes in IL17RB expression can reflect an abnormal state of the glomeruli and are related to the severity of the disease, possessing the potential to serve as a biomarker of glomerular damage.

[0005] To achieve the above-mentioned objectives, the present invention adopts the following technical solution:

[0006] The first aspect of this invention provides the use of IL17RB in the preparation of reagents or kits for monitoring glomerular podocyte function.

[0007] IL17RB, a member of the IL-17 receptor family, initiates downstream signaling pathways by binding to ligands IL-17E / IL-25 and IL-17B, playing a crucial role in the development and progression of some inflammatory diseases, mucosal immune defense, autoimmune diseases, and cancer. However, an association between IL17RB and podocyte damage in chronic kidney disease (CKD) has not yet been found. This invention, through the study of renal tissue specimens from patients with MCD, MN, IgAN, and DKD, reveals for the first time that the expression level of IL17RB in the renal tissues of patients with these four common chronic kidney diseases is significantly higher than that in normal renal tissues. In the overall ROC analysis of all renal disease samples, IL17RB achieved a sensitivity of 80.52% and a specificity of 100% in diagnosing CKD. Furthermore, IL17RB is mainly expressed in glomerular podocytes and exhibits podocyte-specific high expression, suggesting that IL17RB can serve as a marker molecule for early glomerular podocyte damage with high sensitivity and specificity.

[0008] Furthermore, this study found a correlation between IL17RB expression levels and disease severity, suggesting that IL17RB could serve as a broad-spectrum biomarker for monitoring glomerular podocyte function and assessing the severity of chronic kidney disease.

[0009] Preferably, the application is the use of IL17RB in the preparation of reagents or kits for monitoring glomerular podocyte function in patients with minimal change disease, membranous nephropathy, IgA nephropathy, and diabetic nephropathy.

[0010] Preferably, the reagent or kit is used to detect the expression level of IL17RB in renal parenchymal cells.

[0011] Optionally, the reagent or kit is used to detect the expression level of IL17RB in renal parenchymal cells by immunohistochemical staining or immunofluorescence.

[0012] A second aspect of the present invention provides the use of IL17RB in the preparation of reagents or kits for recognizing glomerular damage.

[0013] The lesions of MCD, MN, IgAN, and DKD all focus on glomerular structural and functional damage, and IL17RB is upregulated in the diseased glomeruli, suggesting that the abnormal increase of IL17RB is closely related to glomerular damage and can be used as a marker of glomerular damage in chronic kidney disease, but is not related to the category of these four kidney diseases.

[0014] This invention demonstrates that the expression level of IL17RB in the renal tissue of patients with four common chronic kidney diseases is negatively correlated with the expression of Synaptopodin, and its expression level is associated with blood urea nitrogen (BUN), suggesting that IL17RB has good diagnostic efficacy as a marker of renal tissue damage.

[0015] Preferably, the glomerular injury is glomerular podocyte injury.

[0016] Preferably, the application is the use of the IL17RB in the preparation of reagents or kits for monitoring glomerular damage in patients with minimal change disease, membranous nephropathy, IgA nephropathy and diabetic nephropathy.

[0017] Preferably, the reagent or kit is used to detect the expression level of IL17RB in renal parenchymal cells.

[0018] Preferably, the reagent or kit contains a reagent for detecting the expression level of IL17RB in renal parenchymal cells.

[0019] Optionally, the reagent or kit is used to detect the expression level of IL17RB in renal parenchymal cells by immunohistochemical staining or immunofluorescence.

[0020] A third aspect of the present invention provides the use of IL17RB in the preparation of reagents or kits for assisting in the screening or diagnosis of chronic kidney disease and / or the assessment of chronic kidney disease condition.

[0021] The expression levels of IL17RB in kidney tissue specimens from patients with four common chronic kidney diseases (MCD, MN, IgAN, and DKD) were significantly higher than those in normal kidney tissue, with mean AUC values ​​above 0.92. This suggests that IL17RB can serve as a diagnostic marker for the auxiliary screening or diagnosis of chronic kidney diseases, especially the four types of chronic kidney diseases mentioned above, and can also be used as a marker for the assessment of chronic kidney disease.

[0022] Preferably, the chronic kidney disease includes minimal change disease, membranous nephropathy, IgA nephropathy, and diabetic nephropathy.

[0023] Preferably, the reagent or kit is used to detect the expression level of IL17RB in renal parenchymal cells.

[0024] Preferably, the reagent or kit contains a reagent for detecting the expression level of IL17RB in renal parenchymal cells.

[0025] Optionally, the reagent or kit is used to detect the expression level of IL17RB in renal parenchymal cells by immunohistochemical staining or immunofluorescence.

[0026] The beneficial effects of this invention are as follows: This invention is the first to discover that the expression level of IL17RB in the renal tissue of patients with four glomerular diseases, namely MCD, MN, IgAN and DKD, is significantly higher than that in normal tissue. Moreover, the mean AUC value of IL17RB in distinguishing the above four kidney diseases from normal tissue is above 0.92. Furthermore, IL17RB is located in podocytes, suggesting that IL17RB can serve as a marker molecule for early damage to glomerular podocytes and a diagnostic marker for these four glomerular diseases, with high sensitivity and specificity. Although MCD, MN, IgAN, and DKD exhibit significant differences in their pathogenic mechanisms and histopathological changes, the lesions all focus on glomerular structural and functional damage. This invention also found that IL17RB is associated with BUN in MN and is upregulated in diseased glomeruli. Furthermore, IL17RB expression is negatively correlated with Synaptopodin expression, suggesting that abnormally elevated IL17RB is closely related to glomerular podocyte damage and possesses good diagnostic efficacy, serving as a biomarker reflecting glomerular podocyte damage in chronic kidney disease, regardless of the specific type of chronic kidney disease. After staging the disease based on severity, IL17RB expression was found to be related to the pathological stage of the disease, suggesting that IL17RB can also serve as a biomarker for assessing the severity of chronic kidney disease. This invention is expected to effectively supplement the traditional pathological diagnosis of chronic kidney disease at the molecular level and provide new perspectives and strategies for the clinical diagnosis and mechanistic exploration of glomerular diseases. Attached Figure Description

[0027] Figure 1 This refers to the expression level of IL17RB in podocytes of the kidneys of patients with DKD and IgAN in Example 3 of the present invention;

[0028] Figure 2 The expression levels of IL17RB in renal biopsy specimens from patients with kidney disease and adjacent normal renal tissue in Example 3 of this invention;* P <0.05,** P <0.01, **** P <0.0001;

[0029] Figure 3 The results of immunohistochemical staining with anti-IL17RB were obtained from kidney biopsy specimens from a kidney disease patient and adjacent normal kidney tissue in Example 3 of this invention.

[0030] Figure 4 These are immunofluorescence colocalization images of Synaptopodin and IL17RB in the kidney tissues of DKD patients and control groups in Example 3 of this invention;

[0031] Figure 5 This is the research operating characteristic (ROC) curve of a chronic kidney disease subject in Example 3 of the present invention;

[0032] Figure 6 The correlation between IL17RB expression level and renal function indicators, podocyte marker Synaptopodin, and disease severity in Example 3 of the present invention;

[0033] Figure 7 This illustrates the correlation between IL17RB expression levels and the degree of kidney damage in patients with kidney disease in Example 3 of the present invention.

[0034] Figure 8 The results of immunohistochemical staining with Synaptopodin are shown in Example 3 of this invention, which involves renal biopsy specimens from a patient with kidney disease and normal renal tissue adjacent to cancer.

[0035] Figure 9 Synaptopodin expression levels in renal biopsy specimens from patients with kidney disease and adjacent normal renal tissue in Example 3 of this invention; * P <0.05, **** P <0.0001. Detailed Implementation

[0036] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to specific embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention. All other embodiments obtained by those skilled in the art based on the implementation methods of this invention without inventive effort fall within the protection scope of this invention.

[0037] Unless otherwise specified, all raw materials and reagents used in the following examples were obtained commercially. Unless otherwise specified, all operating methods used in the following examples are conventional operating methods in the art.

[0038] Example 1

[0039] This invention provides a kit for detecting IL17RB expression levels in renal parenchymal cells using immunohistochemical staining. This kit can be used to monitor glomerular podocyte function, identify glomerular damage, and assist in the screening or diagnosis of chronic kidney disease. The reagents in this kit specifically include:

[0040] Paraffin and anti-IL17RB (LS-B15801, Lifespan).

[0041] Example 2

[0042] This invention provides a kit for detecting IL17RB expression levels in renal parenchymal cells using immunofluorescence. This kit can be used to monitor glomerular podocyte function, identify glomerular damage, and assist in the screening or diagnosis of chronic kidney disease. The reagents in this kit specifically include:

[0043] The TSA fluorescent three-label four-color staining kit (catalog number YMTSA0003) includes the following components: rapid reaction buffer (YMTSA0008), PBS, 3% BSA, primary antibody (rabbit anti-IL17RB, Lifespan), polyclonal secondary antibody (goat anti-rabbit, catalog number: YM0007), and TSA fluorescent reaction solution.

[0044] Example 3

[0045] This embodiment provides a method for detecting the expression level of IL17RB in renal parenchymal cells using the kits of Examples 1 and 2, and provides the research process and results of the correlation study between IL17RB and glomerular podocyte function, glomerular injury, and chronic kidney disease.

[0046] 1. Study subjects and clinical data

[0047] Nineteen patients with minimal change disease, 19 patients with membranous nephropathy, 19 patients with IgA nephropathy, and 20 patients with diabetic nephropathy, all diagnosed by renal biopsy and admitted to Bethune Hospital, were selected as the study subjects. Twenty patients with adjacent normal tissue served as the control group. Clinical data of all subjects were collected, including medical history, serum creatinine (Scr), blood urea nitrogen (BUN), uric acid (UA), urinary protein, and 24-hour urinary protein (24-hour up).

[0048] 2. Methods

[0049] 2.1 Bioinformatics Analysis

[0050] Expression profiles of IL17RB in normal human tissues were obtained from the NCBI Gene database. The GSE209781 (DKD) and GSE171314 (IgAN) datasets were downloaded from the GEO database, and differential expression analysis of IL17RB was performed using the limma package in R.

[0051] 2.2 Immunohistochemical staining

[0052] Paraffin sections of 5 μm renal biopsy specimens from patients with nephropathy and adjacent normal renal tissue were collected and immunohistochemically stained using a Roche fully automated immunohistochemical instrument (BenchMark Ultra) with anti-IL17RB (LS-B15801, Lifespan) and Synaptopodin (21064-1-AP, Proteintech, 1:100).

[0053] Quantitative analysis was performed on the immunohistochemical staining results. All intact glomeruli were selected from each slide, and the glomerular outlines were manually delineated. The positive staining area within each glomerular region and the total glomerular area were measured, and the percentage of positive area (Positive Area%) was calculated. The mean value of all measured glomeruli was used to represent the IL17RB expression level of the sample.

[0054] 2.3 Immunofluorescence

[0055] After dewaxing with xylene and hydration with graded ethanol, paraffin sections of renal biopsies from patients with nephropathy underwent antigen retrieval (sections were placed in rapid reaction buffer (YMTSA0008) of the TSA fluorescent three-label four-color staining kit (catalog number YMTSA0003), microwaved for retrieval, and allowed to cool naturally), followed by washing with PBS. A circular motion was drawn around the tissue using a histochemical pen, and 3% BSA was added for blocking at room temperature for 30 min. First-round labeling: the first primary antibody IL17RB (Lifespan, LS-B15801) was added, and incubation was performed overnight in a humidified chamber at 4°C. The following day, after washing with PBS, the HRP-labeled goat anti-rabbit secondary antibody (catalog number: YM0007) from the TSA fluorescent three-label four-color staining kit was added, and incubation was performed at room temperature in the dark for 50 min. After washing with PBS, TSA fluorescent reaction solution was added and incubated for 15 min, followed by washing with PBS. Place the slides in the rapid reaction buffer (YMTSA0008) of the TSA fluorescent three-label four-color staining kit (catalog number YMTSA0003), incubate at 95°C for 25 min to remove the first round of antibody complexes, and wash with PBS after natural cooling. Second round of labeling: Add 3% BSA for blocking at room temperature for 30 min, then add the second primary antibody Synaptopodin (proteintech, 21064-1-AP), and incubate overnight at 4°C. The next day, after washing with PBS, add the HRP-labeled goat anti-rabbit polyclonal antibody (catalog number: YM0007) from the TSA fluorescent three-label four-color staining kit, and incubate at room temperature in the dark for 50 min. Wash with PBS, add another TSA fluorescent reaction solution and incubate for 2-15 min, then wash with PBS. Add DAPI for staining at room temperature in the dark for 10 min, wash with PBS, mount with anti-fluorescence quenching mounting medium, and observe and image under a confocal microscope.

[0056] 2.4 Statistical Methods

[0057] Statistical analysis was performed on the experimental data (10.5.0) from sections 2.1 to 2.3. For continuous data, normality and homogeneity of variance tests were first performed. Data conforming to a normal distribution were expressed as mean ± standard deviation (mean ± standard deviation). The mean ± standard deviation (±s) is used to represent data that do not conform to a normal distribution. The median (interquartile range) is used to represent the median (interquartile range) [M(P). 25 P 75[This is represented by the symbol ]]. For comparisons between groups: if the data satisfy normality and homogeneity of variance, the independent samples t-test is used for comparisons between two independent samples, and one-way ANOVA is used for comparisons between multiple groups; if the data do not satisfy normality or homogeneity of variance, the corresponding nonparametric test is used, i.e., the Wilcoxon rank-sum test is used for comparisons between two independent samples, and the Kruskal-Wallis H test is used for comparisons between multiple groups. Correlation analysis is performed according to the normality of the data, using either Pearson (normal) or Spearman (non-normal) correlation analysis. Receiver operating characteristic (ROC) curves are used to assess the diagnostic efficacy of the indicators. P <0.05 indicates a statistically significant difference.

[0058] 3. Research Results

[0059] 3.1 Expression of IL17RB in the kidney

[0060] Differential gene expression analysis results of GSE209781 (diabetic nephropathy, DKD) and GSE171314 (IgA nephropathy, IgAN) (e.g.) Figure 1 As shown in the figure, although there was no statistical difference, the expression level of IL17RB in podocytes of both DKD and IgAN nephropathy showed an approximately 2-fold increase compared to normal control tissues.

[0061] Based on the above results, it is speculated that IL17RB may be involved in the pathogenesis of kidney disease.

[0062] 3.2 Expression of IL17RB in renal tissue and podocytes of patients with chronic kidney disease

[0063] like Figure 2 As shown, compared with adjacent normal tissues, the expression levels of IL17RB in the MCD group, MN group, IgAN group, and DKD group were significantly increased, and the differences were statistically significant (all...). P <0.05). Among these, the expression level of IL17RB in MCD was also lower than that in MN, IgAN, and DKD, indicating that the severity of MCD lesions was milder than other kidney diseases, suggesting that IL17RB expression may be related to disease severity. Notably, the IL17RB expression levels in the IgAN and DKD groups were approximately twice that of the normal control group, a trend consistent with... Figure 1 The results are consistent with the upregulation of IL17RB expression in the corresponding kidney diseases.

[0064] It is worth noting that IL17RB is expressed in podocytes specifically ( Figure 3Podocytes are located on the outer layer of the glomerular capillary wall, directly surrounding the capillary basement membrane. Normal podocytes have relatively large cell bodies that bulge towards the urinary pole; their cytoplasm forms pseudopodia-like projections that attach to the outer side of the capillary basement membrane. Figure 3 The magnified area shows a podocyte. (See image below.) Figure 3 As shown, IL17RB in podocytes of patients with MCD, MN, IgAN, and DKD was specifically elevated compared to that in normal tissues adjacent to the tumor. It was mainly located in the cytoplasm, and was almost not expressed in intrinsic renal cells such as mesangial cells and vascular endothelial cells in the glomerulus.

[0065] To further confirm the expression of IL17RB in podocytes, immunofluorescence was used to detect the co-localization of IL17RB and the podocyte marker Synaptopodin. The results are as follows: Figure 4 As shown, the green fluorescence signal of Synaptopodin corresponds to the linear distribution of the podocyte process, exhibiting a linear distribution along the glomerular capillary loops within the glomerulus. The red fluorescence signal of IL17RB is contrasted within Synaptopodin, primarily expressed in the cytoplasm of podocytes, with limited expression around the nucleus. Immunofluorescence results showed that the cytoplasm of IL17RB-positive podocytes was surrounded by Synaptopodin-positive podocytes, and their co-localization confirmed the specific expression of IL17RB in podocytes. Furthermore, compared to the control group, the green signal of the podocyte marker Synaptopodin in the renal tissue of patients with nephropathy was significantly weakened, with some areas showing complete signal loss, while the red fluorescence signal of IL17RB was significantly enhanced, and the number of positive cells increased, suggesting that elevated IL17RB expression may be associated with podocyte dysfunction and the progression of nephropathy.

[0066] 4.3 Diagnostic value and related factors of IL-17RB in chronic kidney disease

[0067] Baseline clinical data and serum parameters of patients with the four subtypes of chronic kidney disease included in this study are shown in Table 1. Normal distribution is represented by mean ± standard deviation, and non-normal distribution is represented by median (interquartile range) [M(P)]. 25 P 75 )]express.

[0068] Table 1 Clinical Data and Serum Parameters

[0069]

[0070] To evaluate the diagnostic value of IL17RB expression in renal tissue for different types of kidney disease, this study used adjacent normal renal tissue as a control and plotted receiver operating characteristic (ROC) curves for chronic kidney disease. Figure 5As shown in the figure. The AUC of MCD was 0.762, with a sensitivity of 73.68%, a specificity of 65%, and a cutoff value of 6.004. The AUC of MN was 0.916, with a sensitivity of 78.95%, a specificity of 100%, and a cutoff value of 7.159. The AUC of IgAN was 1.000, with a sensitivity of 100%, a specificity of 100%, and a cutoff value of 7.345. The AUC of DKD was 1.000, with a sensitivity of 100%, a specificity of 100%, and a cutoff value of 7.243. In the total ROC analysis of all kidney disease samples, the AUC was 0.926, with a sensitivity of 80.52%, a specificity of 100%, and a cutoff value of 7.159. Because the ROC sensitivity and specificity of MCD were low, ROC analysis was performed on the remaining groups after removing MCD. The AUC was 0.972 (95% CI: 0.941 to 1.000), the sensitivity was 93.1%, the specificity was 100%, and the cutoff value was 7.159. This demonstrates that IL17RB has good diagnostic efficacy for chronic kidney disease.

[0071] To further explore the clinical significance of elevated IL17RB expression, this study analyzed its correlation with renal function indicators, the podocyte marker synaptopodin, and disease severity. The results showed that in the membranous nephropathy (MN) subgroup, IL17RB expression was also positively correlated with BUN (r=0.531). P =0.016), such as Figure 6 As shown.

[0072] Due to the limited sample size of each disease subtype in this study, it was difficult to conduct detailed subgroup analyses based on existing pathological staging systems (such as the Ervaert classification for DKD, the Lee and Hass classifications for IgAN). To more reasonably assess the gradient changes in the severity of pathological damage under limited sample size, this study integrated and classified patients with the four types of kidney disease into three damage levels—mild, moderate, and severe—based on key indicators described in the pathology reports, including the proportion of glomerular sclerosis, the extent of interstitial fibrosis, and the degree of podocyte damage. This allowed for subsequent stratified statistical analysis, improving statistical power and the reliability of the results. Results are as follows: Figure 7 As shown, there was a statistically significant difference in IL17RB expression between patients with mild and moderate-to-severe CKD.

[0073] The results of immunohistochemical detection of synaptopodin expression are as follows: Figure 8 and Figure 9As shown, compared with the adjacent normal control group, the expression of synaptopodin in MCD, MN, IgAN, and DKD all showed a significant decreasing trend. This result indicates that podocytes are damaged in patients with chronic kidney disease affecting the glomeruli. Analysis of the correlation between IL17RB and synaptopodin expression in the control and disease groups showed a significant negative correlation (r = -0.4101). P <0.001), suggesting that IL17RB could serve as a novel biomarker for glomerular podocyte injury.

[0074] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. Application of IL17RB in the preparation of reagents or kits for monitoring glomerular podocyte function.

2. The application according to claim 1, characterized in that, The application refers to the use of IL17RB in the preparation of reagents or kits for monitoring glomerular podocyte function in patients with minimal change disease, membranous nephropathy, IgA nephropathy, and diabetic nephropathy.

3. The application according to claim 1 or 2, characterized in that, The reagent or kit is used to detect the expression level of IL17RB in renal parenchymal cells.

4. Application of IL17RB in the preparation of reagents or kits for recognizing glomerular damage.

5. The application according to claim 4, characterized in that, The glomerular injury referred to is glomerular podocyte injury.

6. The application according to claim 4, characterized in that, The application refers to the use of IL17RB in the preparation of reagents or kits for monitoring glomerular damage in patients with minimal change disease, membranous nephropathy, IgA nephropathy, and diabetic nephropathy.

7. The application according to any one of claims 4 to 6, characterized in that, The reagent or kit is used to detect the expression level of IL17RB in renal parenchymal cells.

8. Use of IL17RB in the preparation of reagents or kits for the auxiliary screening or diagnosis of chronic kidney disease and / or assessment of chronic kidney disease condition.

9. The application according to claim 8, characterized in that, The chronic kidney diseases mentioned include minimal change disease, membranous nephropathy, IgA nephropathy, and diabetic nephropathy.

10. The application according to claim 8 or 9, characterized in that, The reagent or kit is used to detect the expression level of IL17RB in renal parenchymal cells.

Images